On February 12, 2021, Mydecine Innovations Group (CSE: MYCO; OTC: MYCOF; FSE: 0NFA) (“Mydecine”) closed a bought deal public offering, pursuant to which the company issued 34,500,000 units (the “Units”) at a price of $0.50 per Unit for aggregate gross proceeds of $17,250,000 (“the Offering”). Canaccord Genuity Corp. led the Offering as the underwriter. Mydecine issued 34,500,000 units of the Company at a price of C$0.50 per Unit (the “Issue Price”) for aggregate gross proceeds to the Company of C$17,250,000, which includes the full exercise of the over-allotment option to purchase 4,500,000 Units at the Issue Price.
Mydecine is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing vitality.
Miller Thomson advised Mydecine on the Offering with a team comprising of Lawrence Wilder, Mack Hosseinian and Paul Dimerin (Capital Markets & Securities).
